EIGR
Price:
$1.725
Market Cap:
$2.55M
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clini...[Read more]
Industry
Biotechnology
IPO Date
2014-01-30
Stock Exchange
NASDAQ
Ticker
EIGR
According to Eiger BioPharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.71. This represents a change of -76.85% compared to the average of 3.07 of the last 4 quarters.
The mean historical Current Ratio of Eiger BioPharmaceuticals, Inc. over the last ten years is 7.85. The current 0.71 Current Ratio has changed 804.50% with respect to the historical average. Over the past ten years (40 quarters), EIGR's Current Ratio was at its highest in in the September 2015 quarter at 21.20. The Current Ratio was at its lowest in in the December 2023 quarter at 0.71.
Average
7.85
Median
7.11
Minimum
0.71
Maximum
14.67
Discovering the peaks and valleys of Eiger BioPharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 371.53%
Maximum Annual Current Ratio = 14.67
Minimum Annual Increase = -84.82%
Minimum Annual Current Ratio = 0.71
Year | Current Ratio | Change |
---|---|---|
2023 | 0.71 | -84.82% |
2022 | 4.68 | 35.35% |
2021 | 3.46 | -58.29% |
2020 | 8.29 | 39.94% |
2019 | 5.92 | -41.71% |
2018 | 10.16 | 73.81% |
2017 | 5.85 | -48.92% |
2016 | 11.44 | -22.00% |
2015 | 14.67 | 10.03% |
2014 | 13.33 | 371.53% |
The current Current Ratio of Eiger BioPharmaceuticals, Inc. (EIGR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.95
5-year avg
4.61
10-year avg
7.85
Eiger BioPharmaceuticals, Inc.’s Current Ratio is less than Spero Therapeutics, Inc. (2.68), less than Bolt Biotherapeutics, Inc. (3.16), less than Coherus BioSciences, Inc. (1.25), less than Gracell Biotechnologies Inc. (7.73), less than Neoleukin Therapeutics, Inc. (15.33), less than Cingulate Inc. (7.35), less than Lyra Therapeutics, Inc. (3.64), less than Finch Therapeutics Group, Inc. (3.87), less than Applied Therapeutics, Inc. (1.06), less than X4 Pharmaceuticals, Inc. (4.89), less than Acumen Pharmaceuticals, Inc. (10.43), less than Inozyme Pharma, Inc. (7.68), less than Terns Pharmaceuticals, Inc. (32.99), less than Day One Biopharmaceuticals, Inc. (14.62), less than Connect Biopharma Holdings Limited (12.04), less than Eton Pharmaceuticals, Inc. (1.51), less than Nuvation Bio Inc. (9.57), less than Eledon Pharmaceuticals, Inc. (6.53), less than Spruce Biosciences, Inc. (5.36), less than Werewolf Therapeutics, Inc. (10.10), less than Unicycive Therapeutics, Inc. (3.61), less than Fusion Pharmaceuticals Inc. (10.64),
Company | Current Ratio | Market cap |
---|---|---|
2.68 | $63.24M | |
3.16 | $22.14M | |
1.25 | $125.58M | |
7.73 | $989.87M | |
15.33 | $8.20M | |
7.35 | $15.16M | |
3.64 | $12.37M | |
3.87 | $19.35M | |
1.06 | $1.12B | |
4.89 | $57.64M | |
10.43 | $142.39M | |
7.68 | $180.51M | |
32.99 | $491.80M | |
14.62 | $1.38B | |
12.04 | $55.25M | |
1.51 | $290.14M | |
9.57 | $942.39M | |
6.53 | $239.55M | |
5.36 | $19.96M | |
10.10 | $84.67M | |
3.61 | $55.01M | |
10.64 | $1.83B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eiger BioPharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Eiger BioPharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Eiger BioPharmaceuticals, Inc.'s Current Ratio?
How is the Current Ratio calculated for Eiger BioPharmaceuticals, Inc. (EIGR)?
What is the highest Current Ratio for Eiger BioPharmaceuticals, Inc. (EIGR)?
What is the 3-year average Current Ratio for Eiger BioPharmaceuticals, Inc. (EIGR)?
What is the 5-year average Current Ratio for Eiger BioPharmaceuticals, Inc. (EIGR)?
How does the current Current Ratio for Eiger BioPharmaceuticals, Inc. (EIGR) compare to its historical average?